SB TEMPUS supports more personalised healthcare for each patient by collecting and analysing medical data using AI.
TEMPUS AI
SoftBank Group backed TempusAI's public offering, at $37 per share, will begin trading on Nasdaq Global Select on Friday.
Popular Posts
